Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Healthcare Claims Database Study to Provide Safety Information on Maternal, Fetal and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) During Pregnancy

NCT06393504 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.

NCT NCT06393504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06393504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Healthcare Claims Database Study to Provide Safety Information on Maternal, Fetal and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) During Pregnancy
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Phase
Observational
Overall status
Active, not recruiting
Start date
November 30, 2023
Completion date
April 30, 2028
Enrollment
2,095 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder